Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

ABSTRACT:

Objectives

To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets.

Methods

The BLISS trials compared belimumab 1 and 10 mg/kg versus placebo, all plus standard SLE therapy, over 52 or 76 weeks. Pooled subgroup analyses of week 52 SLE responder index rates (the primary endpoint in both trials) were performed based on demographic characteristics and baseline disease activity indicators. Pooled multivariate analysis was performed to determine predictors of response and treatment effect.

Results

Pooled univariate and multivariate analyses (N=1684) identified baseline factors associated with an increased benefit

SUBMITTER: van Vollenhoven RF 

PROVIDER: S-EPMC3396451 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature